|
Name |
(11R)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
|
Molecular Formula | C18H26O4 | |
IUPAC Name* |
(4R)-16,18-dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-2-one
|
|
SMILES |
C[C@@H]1CCCCCCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1
|
|
InChI |
InChI=1S/C18H26O4/c1-13-9-7-5-3-2-4-6-8-10-14-11-15(19)12-16(20)17(14)18(21)22-13/h11-13,19-20H,2-10H2,1H3/t13-/m1/s1
|
|
InChIKey |
NPMCCMIBMODCMD-CYBMUJFWSA-N
|
|
Synonyms |
(R)-Zearalane; (11R)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one; 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-, (3R)-
|
|
CAS | NA | |
PubChem CID | 5275921 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 306.4 | ALogp: | 6.0 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 22 | QED Weighted: | 0.671 |
Caco-2 Permeability: | -4.847 | MDCK Permeability: | 0.00003270 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 0.99 |
Blood-Brain-Barrier Penetration (BBB): | 0.43 | Plasma Protein Binding (PPB): | 98.39% |
Volume Distribution (VD): | 1.715 | Fu: | 1.52% |
CYP1A2-inhibitor: | 0.953 | CYP1A2-substrate: | 0.189 |
CYP2C19-inhibitor: | 0.887 | CYP2C19-substrate: | 0.068 |
CYP2C9-inhibitor: | 0.55 | CYP2C9-substrate: | 0.97 |
CYP2D6-inhibitor: | 0.922 | CYP2D6-substrate: | 0.316 |
CYP3A4-inhibitor: | 0.492 | CYP3A4-substrate: | 0.062 |
Clearance (CL): | 7.172 | Half-life (T1/2): | 0.545 |
hERG Blockers: | 0.033 | Human Hepatotoxicity (H-HT): | 0.091 |
Drug-inuced Liver Injury (DILI): | 0.433 | AMES Toxicity: | 0.09 |
Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.799 |
Skin Sensitization: | 0.936 | Carcinogencity: | 0.11 |
Eye Corrosion: | 0.134 | Eye Irritation: | 0.965 |
Respiratory Toxicity: | 0.546 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005003 | 0.903 | D07GRH | 0.284 | ||||
ENC002297 | 0.903 | D08VSI | 0.275 | ||||
ENC005007 | 0.775 | D0P6VV | 0.270 | ||||
ENC005005 | 0.704 | D07MGA | 0.268 | ||||
ENC005004 | 0.704 | D00ZFP | 0.253 | ||||
ENC002298 | 0.704 | D03YVO | 0.248 | ||||
ENC003244 | 0.690 | D04JHN | 0.245 | ||||
ENC002701 | 0.690 | D0T3HY | 0.245 | ||||
ENC003158 | 0.667 | D0S5NG | 0.243 | ||||
ENC003872 | 0.644 | D0PG8O | 0.243 |